ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Efficacy"

  • 2015 American Transplant Congress

    Targeting Complement Pathways During Ischemia and Reperfusion: Implications for the Prevention of Delayed Graft Function

    Z. Yu,1 S. Qi,2 M. Lasaro,1 K. Bouchard,1 C. Dow,1 K. Moore,1 Z. Wu,2 A. Barama,2 J. Xu,2 K. Johnson,1 A. Marozsan,1 Y. Wang.1

    1Pre-Clinical Sciences, Alexion Pharmaceutical Inc., Cheshire, CT; 2Department of Surgery, Hôpital Notre Dame and Université de Montréal, Montréal, QC, Canada.

    Complement system plays a critical role in ischemia-reperfusion injury (IRI), and contributes to DGF. The aim of this study was to evaluate the effects of…
  • 2015 American Transplant Congress

    Early Conversion to Everolimus in De Novo Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study

    J. de Fijter, H. Holdaas, A. Speziale, G. Junge, Z. Wang, J. Cruzado, M. van der Giet.

    For the ELEVATE Study, Leiden, Netherlands.

    Purpose: Long-term exposure to calcineurin inhibitors (CNIs) contributes to unfavorable long-term outcomes, including inferior renal function and premature graft loss with vascular lesions, glomerulosclerosis and…
  • 2015 American Transplant Congress

    Everolimus and Early Calcineurin Inhibitor Withdrawal Is Associated With Superior Renal Function: 5-Year Follow-Up of the Randomized PROTECT Liver Transplantation Study

    M. Sterneck, G. Kaiser, N. Heyne, N. Richter, F. Rauchfuss, A. Pascher, P. Schemmer, L. Fischer, C. Klein, S. Nadalin, F. Lehner, U. Settmacher, D. Gotthardt, M. Loss, S. Ladenburger, P. Wimmer, M. Dworak, H. Schlitt.

    PROTECT Study Group, Novartis Pharma GmbH, Germany.

    Purpose: At the end of the 12-month (M) PROTECT core study (NCT00378014), de novo liver transplant recipients (LTxR) who switched from a calcineurin inhibitor (CNI)…
  • 2015 American Transplant Congress

    Treatment of Hepatitis C Virus in Kidney Transplant Recipients With Direct Acting Anti-Viral Agents: Early Results in 12 Cases

    A. Sharfuddin,1 T. Taber,1 M. Mujtaba,1 M. Yaqub,1 D. Mishler,1 P. Kwo,2 R. Vuppalanchi.2

    1Medicine/Nephrology, Indiana University, Indianapolis; 2Medicine/Hepatology, Indiana University, Indianapolis.

    Background: Recently approved direct acting antiviral agents (DAA) for treatment of HCV are interferon sparing allowing an attractive treatment option for kidney transplant recipient with…
  • 2015 American Transplant Congress

    Efficacy and Safety of Once-Daily Everolimus With Minimized Once-Daily Tacrolimus After Liver Transplantation

    P. De Simone,1 P. Carrai,1 L. Coletti,1 A. Precisi,2 D. Campani,3 F. Filipponi.1

    1Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; 2Laboratory, University of Pisa Medical School Hospital, Pisa, Italy; 3Pathology, University of Pisa Medical School Hospital, Pisa, Italy.

    Background: The everolimus (EVR) pharmacokinetic profile allows for its once daily (OD) administration. We tested the efficacy and safety of a combination schedule of OD-EVR…
  • 2015 American Transplant Congress

    Effectiveness of Neovascularization Surrounding Engrafted Islets by Matrigel With Additional Growth Factors in Intramuscular Islet Transplantation

    G. Yoshimatsu,1,2 N. Sakata,2 H. Tsuchiya,2 M. Takita,3 M. Levy,3 B. Naziruddin,3 M. Unno.2

    1Islet Cell Laboratory, Baylor Research Institute, Dallas, TX; 2Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan; 3Baylor Annette C. and Harold C. Simmons Transplant Institute, Dallas, TX.

    Introduction: Intramuscular islet transplantation is one of the promising transplant sites because of safety, easy accessibility and less invasive procedure. However the efficacy of the…
  • 2015 American Transplant Congress

    The Impact of the Arterial Reconstructions On the Living Donor Kidney Graft

    T. Hiramitsu, K. Futamura, M. Okada, K. Ito, M. Tsujita, N. Goto, S. Narumi, Y. Watarai.

    Transplant and Endocrine Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan.

    BackgroundProcurement side of living donor kidney is decided according to the kidney function. We procure the kidney with lower function for the remaining donor kidney…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences